Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
---|---|---|---|---|---|---|
2023 | Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies | Popat, Sanjay; Ahn, Myung-Ju; Ekman, Simon; Leighl, Natasha B; Ramalingam, Suresh S; Reungwetwattana, Thanyanan; Siva, Shankar; Tsuboi, Masahiro; Wu, Yi-Long; CHIH-HSIN YANG | Targeted oncology | 5 | 5 | |
2022 | Sequential Afatinib and Osimertinib in Asian Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer and Acquired T790M: Combined Analysis of Two Global Non-Interventional Studies | Miura, Satoru; Jung, Hyun Ae; Lee, Shin Yup; Lee, Seung Hyeun; Lee, Min Ki; Lee, Yong Chul; Hochmair, Maximilian J; Yang, Cheng-Ta; Märten, Angela; CHIH-HSIN YANG ; Popat, Sanjay | OncoTargets and therapy | 6 | 5 | |
2015 | TIGER-3: A phase 3, open-label, randomized study of rociletinib vs cytotoxic chemotherapy in patients (pts) with mutant EGFR non-small cell lung cancer (NSCLC) progressing on prior EGFR TKI therapy and doublet chemotherapy. | Yang, James Chih-Hsin; Popat, Sanjay; Georgiou, Panos; Miyamoto, Emiko; Isaacson, Jeffrey D.; Wakelee, Heather A. | J. Clin. Oncol. |